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Hypertrophic cardiomyopathy (HCM) is a complex heart disease with a typical pathophy-
siological characteristic, and with a wide scale of morphologic, functional, and clinical
symptoms. The presented case study describes a case of coincidence of a patient with HCM
and bicuspid aortic valve, on which we wanted to point out the benefit of the NMR
examination and efficiency of alcohol septal ablation with a positive result in a long-term
monitoring.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Hypertrophic cardiomyopathy (HCM) was first described in
detail by London forensic pathologist Donald Teare in 1958,
who published pathologic findings of young patients with
sudden death. The oncoming decades brought a large number
of publications describing HCM from many perspectives and
labelling this disease with tens of terms—idiopathic hyper-
trophic subaortic stenosis, muscular subaortic stenosis, or
hypertrophic obstructive cardiomyopathy. In the 1970s came
globally into use the term ‘‘hypertrophic cardiomyopathy’’.
Historically, the HCM was defined as a heart disease, charac-
teristic with myocardium hypertrophy with consequent absence
of any other disease which would initiate the hypertrophych Society of Cardiology.
strava, Cardiovascular De
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Obzˇut).(aortic stenosis, hypertension, amyloidosis, impacts of excessive
sports training, etc.). At present, we know that an important
proportion of patients suffer concurrently from intraventricular
obstruction. Concerning the occurrence of intraventricular
obstruction of bloodstream can be in a simplified way said that
1/3 of patients is without the obstruction, 1/3 has latent
obstruction which will develop only during stress, and 1/3 of
patients has obstruction even in rest conditions. From the
genetic point of view, the HCM is in 60% (which is a limitation
of this definition) an autosomal dominant disease with incom-
plete penetration, caused by mutation of genes coding the
cardiac sarcomeric proteins. Morphologic image at macroscopic
level is characteristic with myocardium hypertrophy, particu-
larly of the left ventricle, which is asymmetric in majorityPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
partement, 17th Listopadu 1790, 708 52 Ostrava, Czech Republic.
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myocyte disarray, disrupted myofibrillar architecture, and defect
of intercellular connection with fibrosis. Prevalence of this
disease is approximately 0.2% and is thus the most frequent
hereditary cardiovascular disease—in the Czech Republic there
are approx. 20,000 patients with hypertrophic cardiomyopathy,
out of which circa 2000–4000 are carriers of the highest risk of
sudden cardiac death [1]. Annual mortality in the non-selected
population was reported to be 1% [2]. The most important
aspect of the novel interpretation of HCM classification should
be in the future particularly the prognostic seriousness of a
given HCM form.
The clinical progress of the disease is very diverse. Some
patients will remain asymptomatic in the course of their life;
with some will develop symptoms of cardiac failure or angina
pectoris, while with other patients the sudden cardiac death
can be the first display of the disease.2. Case study
In the presented study is described a case of a 47-year-old male,
referred to our workplace with diagnosis of a significant aortic
stenosis for selective coronary angiography and other tests, and
preparation before cardio-surgical solution of the valve defect.
Apart from significant overweight, chronic venous insuffi-
ciency, and moderate mixed dyslipidemia, the patient had no
important internal anamnesis. The patient has no childrenFig. 1 – NMRI: left ventricle hypertrophy before the percut
(parasternal long axis equivalent projection).and in his family neither this diagnosis was made nor sudden
death appeared. The patient used perindopril 10 mg p.o. and
metoprolol 50 mg p.o. for about one year. Clinically, the
patient showed dominant expressions of cardiac insuffi-
ciency in class NYHA III, negated the syncope, stenocardia
appeared after a greater stress. ECG examination indicated
hypertrophy of left ventricle together with inverted T waves
and fixed ST depressions in leads V3-6 and II, III, aVF.
Due to his significant obesity with BMI 45, it was very difficult
to examine the patient by transthoracic echocardiogram. In
spite of this, there was evident significant hypertrophy of left
ventricle with septum thickness 31mm, the present gradient
(gradient at rest)—110mmHg—was localized in the left ventricle
outflow tract (LVOT), not on the aortic valve. As there was
suspected presence of bicuspid aortic valve, a trans-oesophageal
echocardiography examination was carried out, which con-
firmed the morphologic finding. Further on was executed NMR
examination of heart, confirming the diagnosis of hypertrophic
cardiomyopathy with evident SAM (systolic anterior movement)
(Fig. 1). From the trans-oesophageal echocardiography, aswell as
NMR (Fig. 2), was determined the area of the bicuspid aortic
valve area (AVA) exceeding 4 cm2 (4.5 according to NMR) without
serious degenerative changes. The ascending aorta was without
signs of dilatation.
After eliminating a significant aortic stenosis and confirming
the HCM diagnosis we decided to execute percutaneous trans-
luminal septal myocardial ablation (PTSMA). First the patient
underwent an coronary angiography—only unimportant wallaneous transluminal septal myocardial ablation (PTSMA)
Fig. 2 – NMRI: Bicuspid aortic valve (with raphe).
Fig. 3 – NMRI: left ventricle hypertrophy after the percutaneous transluminal septal myocardial ablation (PTSMA) (parasternal
long axis equivalent projection).
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applied the echo contrast agent – SonoVue – to display the
segment of vascularization of septal branch of the left anterior
descending artery. After this verification was applied alcohol
using ‘‘OTW-balloon’’ (over the wire). The operation was with-
out complications, the patient was as usual provided with
temporary cardiac stimulation by VVI electrode into the right
ventricle apex, total amount of the administered alcohol was
1.5 ml, there was a periprocedural gradient decrease (Fig. 3).
Already after the completion of the operation, the patient was
without conduction disorder, and therefore the temporary
cardiac stimulation was cancelled the following day. On the
sixth day of hospitalisation the patient was dissmised home.
Apart from the usual echocardiographic checks was exe-
cuted a control NMR after one month and then after one year
(Figs. 4 and 5). After one month, the thickness of myocardium
in the place of ablation was 21 mm. After one year of
observation, in the place of ablation there was a scar with
thickness of myocardium of 16 mm, the subvalvular myocar-
dium thickness was 28 mm and distal myocardium thickness
26 mm (both measurements obtained by NMR imaging).
At present, the patient is in a functional group NYHA II,
without stenocardia and by echocardiography with rest
gradient 8 mmHg in the left ventricle outflow tract.
3. Discussion
The first percutaneous transluminal septal myocardial abla-
tion (PTSMA) was executed by Ulrich Sigwart in 1995, in theFig. 4 – NMRI: left ventricle hypertrophy after percutaneoCzech Republic it was Dr. Hlava´cˇek and subsequently Prof.
Veselka. This method proves to be safe with the selected
group of symptomatic patients with enhancing the quality of
life and perhaps also influencing their prognosis.
The coincidence of HCM and bicuspid aortic valve was
described already in 1990 by Brown on a set of 4 adult
patients [6]. This set did not contain inherent syndromes
with which the coincidence of the two units had been known.
In recent years are slowly turning true assumptions point-
ing out a number of limitations of echocardiography, and on
the other hand occurs a number of positives of nuclear
magnetic resonance in diagnostics and monitoring of patients
with HCM.
Echocardiography remains until now a gold standard in
examination of patients’ with HCM heart morphology. A
fundamental limitation of echocardiography is the limited
ability to examine certain patients, given particularly by
obesity or lung diseases with hyperinflation, mainly the lung
emphysema. Weak points of the transthoracic echocardio-
graphy are the anterolateral segments of the left ventricle,
papillary muscles, and right-side heart sections, including
diagnostics of right-side intraventricular obstruction. On the
other hand, a fundamental limitation of NMR is until now
the impossibility to examine patients with implanted
cardio stimulator. During examination with utilization of
gadolinium, with a normal myocardium occurs its rapid
saturation and subsequently a washing-away of contrast.
Different situation concerns myocardium with fibrotic foci.
In such case occurs an increased saturation by the contrastus transluminal septal myocardial ablation (PTSMA).
Fig. 5 – Pressure gradient between the left ventricle and the aorta before the percutaneous transluminal septal myocardial
ablation (PTSMA).
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be detected cicatricial, non-functional foci in myocardium
(gadolinium hyperenhancement). Number of such foci and
their extent correlate with the IVS thickness, number of
hypokinetic segments, lower EFLK, occurrence of positive
phenotype already at young age, and occurrence of incon-
stant ventricular tachycardia. All this indicates the relation of
the myocardium fibrosis extent and seriousness of disease
including the risk of sudden cardiac death [3].
However, necrosis foci can also be found with a half of
patients suffering from hypertrophy of left ventricle as a
consequence of aortic stenosis or arterial hypertension [4].
Another group of patients with HCM, which can be identified
only with the help of NMR is represented by patients with
small, localized hypertrophy focus. Such cases concern
patients with apical form of HCM, but also a number of
patients with hypertrophy foci in the area of lower or lateral
wall – sometimes so called ‘‘focal HCM’’ [5]. It is thus
probable that heart NMR will soon become a fundamental
examination for patients with HCM or with suspicion on this
diagnosis.4. Conclusion
By the described case study of coincidence of a patient with
HCM and bicuspid aortic valve, we wanted to point out thebenefit of the NMR examination and efficiency of percuta-
neous transluminal septal myocardial ablation. The positive
result persists even after one year with verification by
echocardiography as well as NMR, with re-modelling in the
septum area after alcohol application.
In this case, it would be arguable to indicate the patient for
a surgical myectomy without aortic valve replacement. Mor-
tality of alcohol septal ablation with a correct execution is
1.5%, and is thus comparable to surgical myectomy [7–9]. At
the same time, we are aware that the patient will probably
arrive at aortic valve replacement. Nevertheless, in case of
wrong indication this would mean a re-operation and thus
also a higher periprocedural risk. Heart NMR is a safe and
patient-considerate method, which can help to diagnose
correctly and determine the correct treatment procedure for
the patient.r e f e r e n c e s
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